Thieler Law Corp, member of the Investor Attorney Network, is investigating whether certain officers and directors of ADMA Biologics Inc (NASDAQ: ADMA) violated securities laws in connection with certain financial statements.

The investigation seeks to discover if possible claims on behalf of purchasers of the securities of ADMA Biologics Inc (NASDAQ: ADMA) concerning whether a series of statements by ADMA Biologics Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On July 29, 2016, ADMA Biologics revealed receipt of a complete response letter from the U.S. Food and Drug Administration ("FDA") regarding the Company's RI-002 product.  ADMA Biologics disclosed that the FDA had identified certain outstanding inspection issues and deficiencies at ADMA Biologics third-party contract manufacturers.

Following this news, NASDAQ: ADMA fell more than 17% on intraday trading on August 1, 2016.

Based in Ramsey, New Jersey, and founded in 2004 ADMA Biologics Inc develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases.

If you purchased shares of ADMA Biologics Inc (NASDAQ: ADMA) on or before July 29, 2016, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185